Home » Newsletters » BioWorld Science

BioWorld Science

June 11, 2014

View Archived Issues

Development of a novel diabody for the targeted lysis of Hodgkin's lymphoma cells

Novel HIV-infected, humanized mouse model developed with antiviral PK/PD capabilities

Viral vector-mediated modulation of early transcription in Alzheimer's disease

First phase I results for MSB-0010718C in advanced solid malignancies

Japanese team prepares novel anti-ADAM 28 MAbs

Lupin synthesizes new nACh receptor PAMs

Actelion Pharmaceuticals synthesizes new antimalarials

Roche discloses new pyrazine derivatives with activity as TaR-1 ligands

New boronic acid derivatives reported by Natco Pharma

Pharmacyclics discloses novel protein kinase inhibitors

Novel TRPA1 antagonists disclosed by Roche

EffRx Pharmaceuticals obtains FDA orphan drug status for metformin in PCOS

FDA grants orphan drug status to Makindus' treatment for Stargardt disease

Alchemia provides update on phase III trial of HA-irinotecan in colorectal cancer

NIH-funded tests aim to improve artificial vision technology

Cellectis and Accelera sign agreement for preclinical studies of UCART-19

Symbiomix initiates phase II trial of SYM-1219 for bacterial vaginosis

Biotech consortium launches KPI Therapeutics

Losmapimod begins phase III cardiovascular outcomes trial in acute coronary syndrome

MedImmune to begin phase I study of MEDI-4920

Investigators find novel genetic biomarker for Noonan syndrome

[99mTc]-AVX-128 as a novel radiotracer for apoptosis

Chinese fast track designation granted to epilepsy drug DP-VPA

Isis initiates phase I study of myotonic dystrophy candidate

Karyopharm's selinexor enters phase II trial in prostate cancer

iCo Therapeutics reports topline primary endpoint data from phase II study of iCo-007

Bunavail buccal film approved by FDA for opioid dependence

ONO-4053 shows efficacy in animal models of allergic rhinitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...